OMEROS CORP (OMER)
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
Address
201 ELLIOTT AVENUE WEST
SEATTLE, WA 98119
Founded
1994
Number of Employees
198
Website
http://www.omeros.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s ) |
- | - | - | - | - | - | - | - | - | $4,577 | $11,681 | $8,129 |
| Average Price | - | - | - | - | - | - | - | - | - | $2.54 | $3.66 | $3.25 |
| # Shares Purchased | - | - | - | - | - | - | - | - | - | 1,804,144 | 3,195,241 | 2,499,693 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | - | 18.3% | -17.9% | -7.7% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | - | 31.3% | 7.4% | 19.4% |
| Excess Total Return | - | - | - | - | - | - | - | - | - | -13.1% | -25.3% | -27.1% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | - | 58% | 15% | 37% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
People also followed
Never miss an email alert when insiders at OMER make a trade.
Creating a free account takes less than one minute